EKTABS Stock Overview
A medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Elekta AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 69.88 |
| 52 Week High | SEK 87.93 |
| 52 Week Low | SEK 63.78 |
| Beta | 1.12 |
| 11 Month Change | 0% |
| 3 Month Change | 0.58% |
| 1 Year Change | n/a |
| 33 Year Change | -35.92% |
| 5 Year Change | -41.21% |
| Change since IPO | -79.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| EKTABS | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | 2.2% |
| 1Y | n/a | -2.4% | 8.8% |
Return vs Industry: Insufficient data to determine how EKTABS performed against the UK Medical Equipment industry.
Return vs Market: Insufficient data to determine how EKTABS performed against the UK Market.
Price Volatility
| EKTABS volatility | |
|---|---|
| EKTABS Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: EKTABS's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine EKTABS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1972 | 4,566 | Gustaf Salford | elekta.com |
Elekta AB (publ), a medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. The company offers radiation therapy products, including Elekta Unity for real-time MR visualization; Elekta Versa HD, a brain metastases solution; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; and quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit; Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Leksell GammaPlan, a treatment planning and management software.
Elekta AB (publ) Fundamentals Summary
| EKTABS fundamental statistics | |
|---|---|
| Market cap | SEK 24.57b |
| Earnings (TTM) | SEK 1.13b |
| Revenue (TTM) | SEK 18.12b |
21.7x
P/E Ratio1.4x
P/S RatioIs EKTABS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EKTABS income statement (TTM) | |
|---|---|
| Revenue | SEK 18.12b |
| Cost of Revenue | SEK 11.49b |
| Gross Profit | SEK 6.63b |
| Other Expenses | SEK 5.50b |
| Earnings | SEK 1.13b |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
Nov 27, 2024
| Earnings per share (EPS) | 2.97 |
| Gross Margin | 36.60% |
| Net Profit Margin | 6.26% |
| Debt/Equity Ratio | 60.6% |
How did EKTABS perform over the long term?
See historical performance and comparisonDividends
3.7%
Current Dividend Yield81%
Payout RatioDoes EKTABS pay a reliable dividends?
See EKTABS dividend history and benchmarks| Elekta dividend dates | |
|---|---|
| Ex Dividend Date | Mar 06 2025 |
| Dividend Pay Date | Mar 12 2025 |
| Days until Ex dividend | 99 days |
| Days until Dividend pay date | 105 days |
Does EKTABS pay a reliable dividends?
See EKTABS dividend history and benchmarks